Show simple item record

dc.contributor.authorZafari, Zafar
dc.contributor.authorLi, Shukai
dc.contributor.authorEakin, Michelle N
dc.contributor.authorBellanger, Martine
dc.contributor.authorReed, Robert M
dc.date.accessioned2021-04-07T18:15:59Z
dc.date.available2021-04-07T18:15:59Z
dc.date.issued2020-10-02
dc.identifier.urihttp://hdl.handle.net/10713/15113
dc.description.abstractBackground: In the United States, COPD is a leading cause of mortality, with a substantial societal health and economic burden. With anticipated population growth, it is important for various stakeholders to have an estimate for the projected burden of disease. Research Question: The goal of this study was to model the 20-year health and economic burden of COPD, from 2019 to 2038, in the United States. Study Design and Methods: Using country-specific data from published literature and publicly available datasets, a dynamic open cohort Markov model was developed in a probabilistic Monte Carlo simulation. Population growth was modeled across different subgroups of age, sex, and smoking. The COPD prevalence rates were calibrated for different subgroups, and distributions of severity grades were modeled based on smoking status. Direct costs, indirect absenteeism costs, losses of quality-adjusted life years (QALYs), and number of exacerbations and deaths associated with COPD were projected. Results: The 20-year discounted direct medical costs attributable to COPD were estimated to be $800.90 billion (95% credible interval [CrI], 565.29 billion-1,081.29 billion), with an expected $337.13 billion in male subjects and $463.77 billion in female subjects. The 20-year discounted indirect absenteeism costs were projected to be $101.30 billion (70.82 billion-137.41 billion). The 20-year losses of QALYs, number of exacerbations, and number of deaths associated with COPD were 45.38 million (8.63 million-112.07 million), 315.08 million (228.59 million-425.33 million), and 9.42 million (8.93 million-9.93 million), respectively. The proportion of disease burden attributable to continued smoking was 34% in direct medical costs, 35% in indirect absenteeism costs, and 37% in losses of QALYs over 20 years. Interpretation: This study projects the substantial burden of COPD that the American society is expected to incur with current patterns for treatments and smoking rates. Mitigating such burden requires targeted budget appropriations and cost-effective interventions.en_US
dc.description.urihttps://doi.org/10.1016/j.chest.2020.09.255en_US
dc.language.isoenen_US
dc.publisherElsevier Inc.en_US
dc.relation.ispartofChesten_US
dc.rightsCopyright © 2020 American College of Chest Physicians. Published by Elsevier Inc. All rights reserved.en_US
dc.subjectCOPDen_US
dc.subjectMonte Carlo simulationen_US
dc.subjecteconomic burden projectionen_US
dc.subjecthealth burden projectionen_US
dc.subjectstochastic dynamic Markov modelen_US
dc.titleProjecting Long-Term Health and Economic Burden of COPD in the United Statesen_US
dc.typeArticleen_US
dc.identifier.doi10.1016/j.chest.2020.09.255
dc.identifier.pmid33011203
dc.source.countryUnited States


Files in this item

Thumbnail
Name:
Publisher version

This item appears in the following Collection(s)

Show simple item record